Theme

Investigations of the AstraZeneca vaccine (Vaxzevria)

The Danish Health Authority has decided to continue the COVID-19 vaccine rollout without the vaccine from AstraZeneca. In this theme, you can read about the investigations of the unusual symptoms that were part of the rationale for this decision.

Go to theme
Theme

Vaccines against COVID-19

Medicines agencies around the world are collaborating to approve and follow vaccines against COVID-19. Once the vaccines are approved, medicines authorities around the world follow up with monitoring of adverse drug reactions. Read about results, processes and new vaccines against COVID-19 in our three themes or in the question-and-answer below.

Go to theme
indgangsikon nr 1

General public

Here you can read about reimbursement, drugs affecting the ability to drive and other topics relevant for the general public.

indgangsikon nr 2

Industry

Information on licensing, inspections, fees, company authorisations, clinical trials and more.

indgangsikon nr 3

Healthcare professionals

This section gathers information for doctors, nurses, pharmacies, dentists and other healthcare professionals.

News

EMA to undertake a review of data as to the AstraZeneca vaccine’s efficacy in preventing COVID-19 disease

15 April 2021

The European Medicines Agency (EMA) is undertaking a review of vaccination data of the COVID-19 vaccine from AstraZeneca. The review will include infection rates, hospitalisations, morbidity and mortality. The EMA will also prepare a recommendation for those who have received the first dose of the vaccine.

EMA: The AstraZeneca vaccine possibly causes rare, serious symptoms – but remains authorised for use

08 April 2021

COVID-19 Vaccine AstraZeneca: Investigations of blood clots with low numbers of platelets and bleeding continue in Denmark and in the EU

26 March 2021

Status on the drug regulatory authorities’ investigation of blood clots after vaccination with the AstraZeneca vaccine

18 March 2021